All In Biotech

Drug Trial Radar · NCT02664935

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

423

Actual

Start

May 13, 2015

Primary completion

Nov 29, 2023

Study completion Nov 29, 2023

Sponsor

Lead sponsor
University of BirminghamAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research UK; AstraZeneca; Pfizer; Experimental Cancer Medicine Centres; Mirati Therapeutics Inc.
First posted
Jan 27, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial consists of a series of parallel multi-centre single arm phase II trial arms, each testing an experimental targeted drug in a population stratified by multiple pre-specified actionable target putative biomarkers. The primary objective is to evaluate whether there is a signal of activity in each drug-(putative)biomarker cohort separately. A Bayesian adaptive design is adopted to achieve this objective and statistical details are given in the Protocol.

Conditions

  • Non-Small Cell Lung Cancer
  • Carcinoma, Squamous Cell
  • Adenocarcinoma

Interventions

  • AZD4547Drug

    FGFR Inhibitor

  • VistusertibDrug

    MTORC1/2 Inhibitor

  • PalbociclibDrug

    CDK4/6 Inhibitor

  • CrizotinibDrug

    ALK/MET/ROS1 Inhibitor

  • SelumetinibDrug

    MEK Inhibitor

  • DocetaxelDrug

    Taxane, anti-mitotic cytotoxic chemotherapy

  • AZD5363Drug

    AKT Inhibitor

  • OsimertinibDrug

    EGFRm+ T790M+ Inhibitor

  • DurvalumabDrug

    Anti-PDL1

  • SitravatinibDrug

    VEGFR Inhibitor

  • AZD6738Drug

    ATR inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response (OR)Time frame: From baseline until disease progression, assessed up to 18 months.
  2. Progression-free survival time (PFS)Time frame: From date of commencement of trial treatment to date of CT scan when progressive disease first recorded or date of death without previously recorded progression, assessed up to 18 months.
  3. Durable clinical benefit (DCB)Time frame: From baseline until the first scan after 24 weeks showing the patient free of disease progression.

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom

  • Belfast City Hospital, Belfast Health and Social Care Trust

    Belfast, United Kingdom

  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust

    Birmingham, United Kingdom

  • Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust

    Birmingham, United Kingdom

  • University Hospitals Bristol NHS Foundation Trust

    Bristol, United Kingdom

  • Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom

  • Velindre Cancer Centre, Velindre NHS Trust

    Cardiff, United Kingdom

  • Colchester General Hospital

    Colchester, United Kingdom

  • Edinburgh Cancer Centre, Western General Hospital

    Edinburgh, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, United Kingdom

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • St. James' University Hospital, Leeds Teaching Hospital NHS Trust

    Leeds, United Kingdom

  • Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust

    Leicester, United Kingdom

  • Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust

    London, United Kingdom

  • Charing Cross Hospital, Imperial College Healthcare NHS Trust

    London, United Kingdom

  • Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust

    London, United Kingdom

  • St Bartholomew's Hospital, Barts Health NHS Trust

    London, United Kingdom

  • University College Hospital, University College London Hospitals NHS Foundation Trust

    London, United Kingdom

  • Maidstone Hospital

    Maidstone, United Kingdom

  • The Christie Hospital, The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Clatterbridge Cancer Centre

    Metropolitan Borough of Wirral, United Kingdom

  • Sir Bobby Robson Cancer Trial Research Centre, The Newcastle upon Tyne Hospitals

    Newcastle, United Kingdom

  • Churchill Hospital, Oxford University Hospitals NHS Foundation Trust

    Oxford, United Kingdom

  • Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust

    Sheffield, United Kingdom

  • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.